Medication info
Janurit 50mg (Sitagliptin Hydrochloride Monohydrate)

Janurit 50mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›128.5mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Round, biconvex, film-coated tablet of light yellow-pink color
Packaging
30 tablets - 10 tablets/PTP[x3]
Approval status
Active

MFDS item code 202002249 · Approved 2020.03.31 · Insurance code 671807150

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This drug is administered at 100 mg once daily, as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken regardless of meals. When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, renal function should be assessed before treatment and periodically thereafter. 1. No dosage adjustment is required for patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required for patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. For patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. For patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to help improve blood sugar control in patients with type 2 diabetes. It can be administered alone or in conjunction with dietary and exercise therapy, and is used during initial therapy for diabetes. If blood sugar control is difficult with monotherapy, it can be used in combination with metformin. Additionally, it can be co-administered with other diabetes treatments such as sulfonylureas, thiazolidinediones, and insulin. If multiple medications are prescribed and blood sugar control is still inadequate, this drug can be added to enhance therapeutic effect. This medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

This drug is administered at 100 mg once daily, as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken regardless of meals. When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, renal function should be assessed before treatment and periodically thereafter. 1. No dosage adjustment is required for patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required for patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. For patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. For patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.

Precautions

This medication may cause hypersensitivity reactions, so if allergic symptoms or skin rashes, dyspnea, etc. occur, discontinue use immediately and consult a doctor. ACute pancreatitis may occur, so notify medical personnel immediately if symptoms such as abdominal pain, vomiting, or loss of appetite arise. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication, and it should be avoided in cases of hypersensitivity to this drug or its components. Patients with reduced renal function need dose adjustments, hence regular kidney function tests should be conducted and the medication should be taken according to the physician's instructions. This drug may induce hypoglycemia, so particularly when taken with insulin or sulfonylureas, blood sugar levels should be checked frequently and hypoglycemic symptoms need to be monitored. If severe joint pain or skin blistering symptoms occur, it is necessary to consult a doctor immediately and discontinue the medication. Pregnant or breastfeeding women are advised to avoid using this medication, and safety in pediatric and adolescent populations under 18 years of age has not been established. Elderly patients should periodically evaluate kidney function before and after taking this medication as renal function may decline. In case of overdose, visit a medical institution immediately for proper treatment, and some medications may be removed through hemodialysis. This medication has minimal interactions with other drugs, but caution is needed when used with certain medications, so inform the doctor or pharmacist of any other medications being taken.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infection
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 27 more
  • nausea
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • blistering similar to pemphigus
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is recommended to be stored at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Round, biconvex, film-coated tablet of light yellow-pink color

Package unit

30 tablets - 10 tablets/PTP[x3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.